IDEAYA Biosciences (IDYA)

IDEAYA combines drug discovery with translational biology and biomarker development. Its research focuses heavily on synthetic lethality, a cancer biology concept in which blocking a particular pathway can be especially harmful to tumor cells that already carry certain genetic defects, while sparing normal cells to a greater extent. The company uses molecular diagnostics and biomarker work to define which patients may be most appropriate for its programs.

The pipeline includes several clinical-stage and development-stage candidates across solid tumors. Darovasertib targets protein kinase C and is being studied in cancers such as uveal melanoma. IDE397 targets MAT2A, a pathway relevant to tumors with MTAP deletion. Other programs include assets directed at DLL3, Werner helicase, PARG, and polymerase theta helicase, reflecting the company’s emphasis on DNA damage repair, replication stress, and tumor-specific dependencies. IDEAYA also maintains earlier preclinical discovery programs that may expand its pipeline over time.

As a Nasdaq-listed company under the IDYA symbol, IDEAYA operates in the high-risk, high-potential oncology biotech market. Its value is tied to clinical trial progress, regulatory outcomes, partnerships, and the ability to show that biomarker-selected therapies can produce meaningful benefits for patients with difficult-to-treat cancers.